Render Target: SSR
Render Timestamp: 2024-11-29T15:53:06.568Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-10-16 17:30:23.305
Product last modified at: 2024-07-17T20:30:09.335Z
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a
  1. Products /
  2. Primary Antibodies /
  3. Human Reactive DNA Demethylation Antibody Sampler Kit

Human Reactive DNA Demethylation Antibody Sampler Kit #84884

    Product Information

    Kit Usage Information

    Protocols

    Product Description

    The Human Reactive DNA Demethylation Antibody Sampler Kit provides an economical means of detecting TET protein family members and TDG protein. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

    Background

    Methylation of DNA at cytosine residues is a heritable, epigenetic modification that is critical for proper regulation of gene expression, genomic imprinting, and mammalian development (1,2). 5-methylcytosine is a repressive epigenetic mark established de novo by two enzymes, DNMT3a and DNMT3b, and is maintained by DNMT1 (3,4). 5-methylcytosine was originally thought to be passively depleted during DNA replication. However, subsequent studies have shown that Ten-Eleven Translocation (TET) proteins TET1, TET2, and TET3 can catalyze the oxidation of methylated cytosine to 5-hydroxymethylcytosine (5-hmC) (5). Additionally, TET proteins can further oxidize 5-hmC to form 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), both of which are excised by thymine-DNA glycosylase (TDG), effectively linking cytosine oxidation to the base excision repair pathway and supporting active cytosine demethylation (6,7). TET1 is highly expressed in embryonic stem cells and is essential for maintaining stem cell pluripotency (8). Aberrant TET1 expression has also been implicated in a variety of cancers, including hepatocellular carcinoma, T-cell acute lymphoblastic leukemia (T-ALL), and triple-negative breast cancer (TNBC), among others (9-11). TET2 is frequently mutated in myeloid dysplastic syndrome (MDS) and diffuse large B-cell lymphomas (12,13). TET2 protein expression is often reduced in solid tumors such as prostate cancer, melanoma, and oral squamous cell carcinoma (14-16). TET3 plays key roles in regulating early development and neonatal growth (17,18). TET2/TET3 deficiency can lead to myeloid cell, B cell, and invariant natural killer T (iNKT) cell malignancies. In Tregs, TET2/TET3 deficiency in mice leads to hyperproliferation and inflammatory disease (19,20). Knockout or catalytic inactivation of TDG leads to embryonic lethality (21,22). SUMOylation of TDG has been reported to help it dissociate from its abasic product, thereby increasing catalytic turnover (23). Additional studies suggest that SUMOylation affects TDG’s cellular localization or lowers its base excision activity, allowing it to act as a ‘reader’ protein for 5-fC and 5-caC modified DNA (24).
    1. Hermann, A. et al. (2004) Cell Mol Life Sci 61, 2571-87.
    2. Turek-Plewa, J. and Jagodziński, P.P. (2005) Cell Mol Biol Lett 10, 631-47.
    3. Okano, M. et al. (1999) Cell 99, 247-57.
    4. Li, E. et al. (1992) Cell 69, 915-26.
    5. Tahiliani, M. et al. (2009) Science 324, 930-5.
    6. He, Y.F. et al. (2011) Science 333, 1303-7.
    7. Ito, S. et al. (2011) Science 333, 1300-3.
    8. Ito, S. et al. (2010) Nature 466, 1129-33.
    9. Shirai, K. et al. (2021) Cancer Sci 112, 2855-2869.
    10. Bamezai, S. et al. (2021) Leukemia 35, 389-403.
    11. Good, C.R. et al. (2018) Cancer Res 78, 4126-4137.
    12. Langemeijer, S.M. et al. (2009) Nat Genet 41, 838-42.
    13. Asmar, F. et al. (2013) Haematologica 98, 1912-20.
    14. Nickerson, M.L. et al. (2013) Hum Mutat 34, 1231-41.
    15. Lian, C.G. et al. (2012) Cell 150, 1135-46.
    16. Jäwert, F. et al. (2013) Anticancer Res 33, 4325-8.
    17. Peat, J.R. et al. (2014) Cell Rep 9, 1990-2000.
    18. Tsukada, Y. et al. (2015) Sci Rep 5, 15876.
    19. Nakatsukasa, H. et al. (2019) Int Immunol 31, 335-347.
    20. Yue, X. et al. (2019) Nat Commun 10, 2011.
    21. Cortellino, S. et al. (2011) Cell 146, 67-79.
    22. Cortázar, D. et al. (2011) Nature 470, 419-23.
    23. Hardeland, U. et al. (2002) EMBO J 21, 1456-64.
    24. Coey, C.T. and Drohat, A.C. (2018) Nucleic Acids Res 46, 5159-5170.

    Database Links

    UniProt ID: O43151 , Q6N021 , Q13569 , Q8NFU7


    Entrez-Gene Id: 200424 , 54790 , 6996 , 80312


    限制使用

    除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。

    专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.